Gastrointestinal Malignancies in the Era of Precision Oncology: From Bench to Bedside and Back Again (Volume II)

Dear Colleagues,

This collection is the second edition of a previous one, "Gastrointestinal Malignancies in the Era of Precision Oncology: From Bench to Bedside and Back Again" (https://www.mdpi.com/journal/cancers/special_issues/Gastrointestinal_Malignancies_Precision_Oncology_From_Bench_Bedside).

Physicians’ and researchers’ approaches to cancer are dramatically changing. Growing the knowledge of human genetics and finding insights into the links between chronic inflammation, immune system, microbiota and cancer development are some of the key steps contributing to advancing the era of precision oncology, as observed in recent years.

By using the same approach of precision medicine, and with the help of innovative techniques for data analysis including artificial intelligence (i.e., machine learning, deep learning, neural networks), a multidisciplinary team mainly composed of clinicians, surgeons, pathologists, radiologists, biostatisticians, geneticists and biologists surround the cancer patient in order to achieve molecular targeted and immune-based therapeutics across a variety of malignancies.

Gastrointestinal malignancies still have high tumor incidence and mortality rate worldwide, with a significant diversity in terms of prognosis and therapeutic response. There is an urgent need for the identification of suitable targets for tailor-made, personalized therapy in this field.

The aim of this Special Issue is to gather top experts covering all aspects of precision oncology for gastrointestinal cancer in 2021, from bench to bedside, and back again.

Dr. Alessandra Soriano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gastrointestinal cancer
• precision medicine
• immunity
• gene expression profiling
• biomarker
• molecular targeted therapy
• liquid biopsy
• circulating tumor cells (CTCs)
• immunotherapy
• machine learning
• organoids